C-reactive protein (CRP) as a predictive marker for outcomes with avelumab plus axitinib (A plus Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101.
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要